This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring
3 days in-person. 3 days virtually.
March 20–22, 2023 | Basel, SwitzerlandMarch 28–30, 2023 | Digital

Carole Nuechterlein
Head, Roche Venture Fund at F.Hoffmann-La Roche


Carole Nuechterlein has headed the Roche Venture Fund since 2001. Prior to her current position, she worked in the pharmaceutical/biotech industry as an attorney for ten years. She joined Roche from SangStat in Fremont California where she was General Counsel.

She currently serves as a director at Aligos Therapeutics, Arch Oncology, CiVi Biopharma, Entrada Therapeutics, Enthera Pharmaecuticals, Mission Therapeutics, Second Genome and Vivet Therapeutics. She was formerly a director at Allakos and AveXis.

She has a BA from Valparaiso University and a JD from University of Michigan.

More information on the Roche Venture Fund can be found at

Agenda Sessions

  • Shifting approaches to investment and how investors collaborate